UPDATE 1-Blow to Roche's cancer immunotherapy prospects as 2nd trial fails

By Reuters

Development of a new cancer immunotherapy pioneered by Roche was thrown in doubt on Wednesday when its drug tiragolumab failed to slow the progression of lung cancer in a second trial. In a study, a combination of tiragolumab and Roche's established Tecentriq drug did not reduce the rate of disease progression in newly diagnosed cases of advanced non-small cell lung cancer when compared to a comparative group of patients on Tecentriq only. That was after the Swiss drugmaker said in March the drug failed to slow the progression of a different, more aggressive form of lung cancer.

…read more

Via:: Sports Headlines


Get 20% off hat purchases for ONLY $5! Join our LIDS Club @ lids.com.
%d bloggers like this: